Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01309542 · ClinicalTrials.gov registry record · Phase 3
Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,403
- Enrollment target
NCT01309542: Completed Phase 3 study, sponsored by Pfizer.
NCT01309542 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,403 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01309542, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,403 participants
- Enrollment target
Study Summary
The study evaluated the long-term safety of Desvenlafaxine Succinate (DVS) Slow Release (SR) during open-label treatment in adult outpatients who had a primary diagnosis of major depressive disorder (MDD). The study also evaluated the long-term response of subjects receiving DVS SR for clinical global evaluation, functionality, general well-being, pain, and absence of depressive symptoms (remission).
Interventions
- DRUG Desvenlafaxine Succinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,403 participants |
| Start Date | 2003-08 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
What the finished NCT01309542 record still lists
NCT01309542 is an interventional study that assigns participants to a tested intervention. Its 1,403 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% higher).
The record links to 0 conditions, and to 1 intervention - of which Desvenlafaxine Succinate is the first listed.
NCT01309542 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01309542 about?
NCT01309542 is a clinical study titled "Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder". The study evaluated the long-term safety of Desvenlafaxine Succinate (DVS) Slow Release (SR) during open-label treatment in adult outpatients who had a primary diagnosis of major depressive disorder (MDD). The study also evaluated the long-term response of subjects receiving DVS SR for clinical glob...
What is the current status of trial NCT01309542?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,403 participants. The study started on 2003-08. Estimated completion is 2006-03.
What interventions are being tested in trial NCT01309542?
The interventions under investigation include: Desvenlafaxine Succinate (DRUG).
Who is sponsoring clinical trial NCT01309542?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01309542's enrollment target sits among peer trials
1,403 172nd of 2000 higher than 1,829 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05444582 · 1,404 participants · Phase 4
Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start
- NCT05992935 · 1,405 participants · Phase 1
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
- NCT02205762 · 1,400 participants · Phase 2
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
- NCT02445222 · 1,400 participants · Phase 3
CAR-T Long Term Follow Up (LTFU) Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia